# A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

> **NCT00620594** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 183 (actual)

## Conditions studied

- Breast Cancer
- Advanced Solid Tumors
- Cowden Syndrome

## Interventions

- **DRUG:** BEZ235

## Key facts

- **NCT ID:** NCT00620594
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12-21
- **Primary completion:** 2013-01-08
- **Final completion:** 2013-01-08
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00620594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00620594, "A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00620594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*